-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Severe -X- _ O
acute -X- _ O
respiratory -X- _ O
syndrome -X- _ O
( -X- _ O
SARS -X- _ O
) -X- _ O
emerged -X- _ O
in -X- _ O
China -X- _ O
in -X- _ O
2002 -X- _ O
and -X- _ O
spread -X- _ O
to -X- _ O
other -X- _ O
countries -X- _ O
before -X- _ O
brought -X- _ O
under -X- _ O
control. -X- _ O
Because -X- _ O
of -X- _ O
a -X- _ O
concern -X- _ O
for -X- _ O
reemergence -X- _ O
or -X- _ O
a -X- _ O
deliberate -X- _ O
release -X- _ O
of -X- _ O
the -X- _ O
SARS -X- _ O
coronavirus -X- _ O
, -X- _ O
vaccine -X- _ O
development -X- _ O
was -X- _ O
initiated. -X- _ O
Evaluations -X- _ O
of -X- _ O
an -X- _ O
inactivated -X- _ O
whole -X- _ O
virus -X- _ O
vaccine -X- _ O
in -X- _ O
ferrets -X- _ O
and -X- _ O
nonhuman -X- _ O
primates -X- _ O
and -X- _ O
a -X- _ O
virus-like-particle -X- _ O
vaccine -X- _ O
in -X- _ O
mice -X- _ O
induced -X- _ O
protection -X- _ O
against -X- _ O
infection -X- _ O
but -X- _ O
challenged -X- _ O
animals -X- _ O
exhibited -X- _ O
an -X- _ O
immunopathologic-type -X- _ O
lung -X- _ O
disease. -X- _ O
DESIGN -X- _ O
: -X- _ O
Four -X- _ B-Intervention
candidate -X- _ I-Intervention
vaccines -X- _ I-Intervention
for -X- _ O
humans -X- _ O
with -X- _ O
or -X- _ O
without -X- _ O
alum -X- _ O
adjuvant -X- _ O
were -X- _ O
evaluated -X- _ O
in -X- _ O
a -X- _ O
mouse -X- _ O
model -X- _ O
of -X- _ O
SARS -X- _ O
, -X- _ O
a -X- _ O
VLP -X- _ B-Intervention
vaccine -X- _ I-Intervention
, -X- _ I-Intervention
the -X- _ I-Intervention
vaccine -X- _ I-Intervention
given -X- _ I-Intervention
to -X- _ I-Intervention
ferrets -X- _ I-Intervention
and -X- _ I-Intervention
NHP -X- _ I-Intervention
, -X- _ I-Intervention
another -X- _ I-Intervention
whole -X- _ I-Intervention
virus -X- _ I-Intervention
vaccine -X- _ I-Intervention
and -X- _ I-Intervention
an -X- _ I-Intervention
rDNA-produced -X- _ I-Intervention
S -X- _ I-Intervention
protein. -X- _ I-Intervention
Balb -X- _ B-Patient
/ -X- _ I-Patient
c -X- _ I-Patient
or -X- _ I-Patient
C57BL -X- _ I-Patient
/ -X- _ I-Patient
6 -X- _ I-Patient
mice -X- _ I-Patient
were -X- _ O
vaccinated -X- _ O
IM -X- _ O
on -X- _ O
day -X- _ O
0 -X- _ O
and -X- _ O
28 -X- _ O
and -X- _ O
sacrificed -X- _ O
for -X- _ O
serum -X- _ O
antibody -X- _ O
measurements -X- _ O
or -X- _ O
challenged -X- _ O
with -X- _ O
live -X- _ O
virus -X- _ O
on -X- _ O
day -X- _ O
56. -X- _ O
On -X- _ O
day -X- _ O
58 -X- _ O
, -X- _ O
challenged -X- _ O
mice -X- _ O
were -X- _ O
sacrificed -X- _ O
and -X- _ O
lungs -X- _ O
obtained -X- _ O
for -X- _ O
virus -X- _ O
and -X- _ O
histopathology. -X- _ O
RESULTS -X- _ O
: -X- _ O
All -X- _ B-Outcome
vaccines -X- _ I-Outcome
induced -X- _ I-Outcome
serum -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
with -X- _ I-Outcome
increasing -X- _ I-Outcome
dosages -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
alum -X- _ I-Outcome
significantly -X- _ I-Outcome
increasing -X- _ I-Outcome
responses. -X- _ I-Outcome
Significant -X- _ I-Outcome
reductions -X- _ I-Outcome
of -X- _ I-Outcome
SARS-CoV -X- _ I-Outcome
two -X- _ I-Outcome
days -X- _ I-Outcome
after -X- _ I-Outcome
challenge -X- _ I-Outcome
was -X- _ I-Outcome
seen -X- _ I-Outcome
for -X- _ I-Outcome
all -X- _ I-Outcome
vaccines -X- _ I-Outcome
and -X- _ I-Outcome
prior -X- _ I-Outcome
live -X- _ I-Outcome
SARS-CoV. -X- _ I-Outcome
All -X- _ I-Outcome
mice -X- _ I-Outcome
exhibited -X- _ I-Outcome
histopathologic -X- _ I-Outcome
changes -X- _ I-Outcome
in -X- _ I-Outcome
lungs -X- _ I-Outcome
two -X- _ I-Outcome
days -X- _ I-Outcome
after -X- _ I-Outcome
challenge -X- _ I-Outcome
including -X- _ I-Outcome
all -X- _ I-Outcome
animals -X- _ I-Outcome
vaccinated -X- _ I-Outcome
( -X- _ I-Outcome
Balb -X- _ I-Outcome
/ -X- _ I-Outcome
C -X- _ I-Outcome
and -X- _ I-Outcome
C57BL -X- _ I-Outcome
/ -X- _ I-Outcome
6 -X- _ I-Outcome
) -X- _ I-Outcome
or -X- _ I-Outcome
given -X- _ I-Outcome
live -X- _ I-Outcome
virus -X- _ I-Outcome
, -X- _ I-Outcome
influenza -X- _ I-Outcome
vaccine -X- _ I-Outcome
, -X- _ I-Outcome
or -X- _ I-Outcome
PBS -X- _ I-Outcome
suggesting -X- _ I-Outcome
infection -X- _ I-Outcome
occurred -X- _ I-Outcome
in -X- _ I-Outcome
all. -X- _ I-Outcome
Histopathology -X- _ I-Outcome
seen -X- _ I-Outcome
in -X- _ I-Outcome
animals -X- _ I-Outcome
given -X- _ I-Outcome
one -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
SARS- -X- _ I-Outcome
CoV -X- _ I-Outcome
vaccines -X- _ I-Outcome
was -X- _ I-Outcome
uniformly -X- _ I-Outcome
a -X- _ I-Outcome
Th2-type -X- _ I-Outcome
immunopathology -X- _ I-Outcome
with -X- _ I-Outcome
prominent -X- _ I-Outcome
eosinophil -X- _ I-Outcome
infiltration -X- _ I-Outcome
, -X- _ I-Outcome
confirmed -X- _ I-Outcome
with -X- _ I-Outcome
special -X- _ I-Outcome
eosinophil -X- _ I-Outcome
stains. -X- _ I-Outcome
The -X- _ I-Outcome
pathologic -X- _ I-Outcome
changes -X- _ I-Outcome
seen -X- _ I-Outcome
in -X- _ I-Outcome
all -X- _ I-Outcome
control -X- _ I-Outcome
groups -X- _ I-Outcome
lacked -X- _ I-Outcome
the -X- _ I-Outcome
eosinophil -X- _ I-Outcome
prominence. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
These -X- _ B-Outcome
SARS-CoV -X- _ I-Outcome
vaccines -X- _ I-Outcome
all -X- _ I-Outcome
induced -X- _ I-Outcome
antibody -X- _ I-Outcome
and -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
infection -X- _ I-Outcome
with -X- _ I-Outcome
SARS-CoV. -X- _ I-Outcome
However -X- _ O
, -X- _ O
challenge -X- _ B-Outcome
of -X- _ I-Outcome
mice -X- _ I-Outcome
given -X- _ I-Outcome
any -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
vaccines -X- _ I-Outcome
led -X- _ I-Outcome
to -X- _ I-Outcome
occurrence -X- _ I-Outcome
of -X- _ I-Outcome
Th2-type -X- _ I-Outcome
immunopathology -X- _ I-Outcome
suggesting -X- _ I-Outcome
hypersensitivity -X- _ I-Outcome
to -X- _ I-Outcome
SARS-CoV -X- _ I-Outcome
components -X- _ I-Outcome
was -X- _ I-Outcome
induced. -X- _ I-Outcome
Caution -X- _ O
in -X- _ O
proceeding -X- _ O
to -X- _ O
application -X- _ O
of -X- _ O
a -X- _ O
SARS-CoV -X- _ O
vaccine -X- _ O
in -X- _ O
humans -X- _ O
is -X- _ O
indicated -X- _ O
. -X- _ O

